Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Catalyst Pharmaceuticals, Inc., Celldex Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Latest Biotechnology and Catalyst Pharmaceuticals, Inc., Celldex Therapeutics, Inc. Stock News

As of February 25, 2026, Catalyst Pharmaceuticals, Inc. had a $3.1 billion market capitalization, compared to the Biotechnology median of $283.1 million. Catalyst Pharmaceuticals, Inc.’s stock is up 3.8% in 2026, down 0.8% in the previous five trading days and up 16.99% in the past year.

Currently, Catalyst Pharmaceuticals, Inc.’s price-earnings ratio is 14.6. Catalyst Pharmaceuticals, Inc.’s trailing 12-month revenue is $578.2 million with a 37.6% net profit margin. Year-over-year quarterly sales growth most recently was 15.3%. Analysts expect adjusted earnings to reach $2.542 per share for the current fiscal year. Catalyst Pharmaceuticals, Inc. does not currently pay a dividend.

As of February 25, 2026, Celldex Therapeutics, Inc. had a $2.0 billion market cap, putting it in the 55th percentile of all stocks. Celldex Therapeutics, Inc.’s stock is up 10.6% in 2026, up 27.6% in the previous five trading days and up 44.49% in the past year.

Currently, Celldex Therapeutics, Inc. does not have a price-earnings ratio. Celldex Therapeutics, Inc.’s trailing 12-month revenue is $2.6 million with a % net profit margin. As of February 25, 2026, Celldex Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-3.589 per share for the current fiscal year. Celldex Therapeutics, Inc. does not currently pay a dividend.

How We Compare Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Catalyst Pharmaceuticals, Inc.	CPRX	B
Celldex Therapeutics, Inc.	CLDX	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Catalyst Pharmaceuticals, Inc. has a Growth Score of 68, which is Strong. Celldex Therapeutics, Inc. has a Growth Score of 29, which is Weak.

The Growth Grade Winner: Catalyst Pharmaceuticals, Inc.

As you can clearly see from the Growth Grade breakdown above, Catalyst Pharmaceuticals, Inc. has a more attractive growth grade than Celldex Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Catalyst Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Catalyst Pharmaceuticals, Inc.	CPRX	A
Celldex Therapeutics, Inc.	CLDX	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Catalyst Pharmaceuticals, Inc. has a Quality Score of 84, which is Very Strong. Celldex Therapeutics, Inc. has a Quality Score of 34, which is Weak.

The Quality Grade Winner: Catalyst Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Catalyst Pharmaceuticals, Inc. has a better overall quality grade than Celldex Therapeutics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Catalyst Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Catalyst Pharmaceuticals, Inc.	CPRX	C
Celldex Therapeutics, Inc.	CLDX	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Catalyst Pharmaceuticals, Inc. has a Earnings Estimate Score of 58, which is Neutral. Celldex Therapeutics, Inc. has a Earnings Estimate Score of 26, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Catalyst Pharmaceuticals, Inc., Celldex Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Catalyst Pharmaceuticals, Inc., Celldex Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc. Grades

In addition to Growth, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Catalyst Pharmaceuticals, Inc., Celldex Therapeutics or Inc. Stock?

Overall, Catalyst Pharmaceuticals, Inc. stock has a Growth Score of 68, Estimate Revisions Score of 58 and Quality Score of 84.

Celldex Therapeutics, Inc. stock has a Growth Score of 29, Estimate Revisions Score of 26 and Quality Score of 34.

Comparing Catalyst Pharmaceuticals, Inc., Celldex Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.